Question-and-Answer Session
Operator
(Operator Instructions). Your first question comes from the line of Andrew Vaino of Roth Capital
Andrew Vaino - Roth Capital
Hey, I just had a quick question. Did I miss what you -- the first thing you talked about, the therapeutic area on your first new compound, did you mentioned what that was?
Jonathan Lim
No, we did not, but it’s a multi-billion therapeutic area with targeting recombinant proteins.
Andrew Vaino - Roth Capital
Okay, and also looking at the PEGylated PH, I know that typically PEGylation doesn’t in invoke immune responses, it does not necessary does the opposite, is there is any indication that PEGylation of the hyaluronidase will give rise to an immune response?
Gregory Frost
No nothing to date that would suggest that to be the case.
Andrew Vaino - Roth Capital
Okay, I was also interested in how you control the activity of the product that indicated for destroying the cellulite dimples, can you mention how you control it, I assume you modify the enzyme a little bit, what are you doing there?
Jonathan Lim
Andrew we are going to be reviewing more information about these enzymes in the coming months. So stay tuned on that front.
Andrew Vaino - Roth Capital
Okay, that’s all right. It’s just that can you then mention sort of what range can you control, or you can control, half-life in terms of minutes, seconds
Gregory Frost
We can actually control -- we have for example variance where we can control it down to having it active for a period of seconds to a period of less than 10 minutes.
Andrew Vaino - Roth Capital
Okay great thank you very much.
Jonathan Lim
You are welcome.
Andrew Vaino - Roth Capital
Thank you
Gregory Frost
You are welcome
Operator
Your next question comes from the line of Eun Yang of Jefferies & Company.
Eun Yang - Jefferies & Company
My first question is about Chemophase, you guys mentioned that you want to initiate the fibrillar trials in the fourth quarter this year. Are we still going to see the Phase I/II data in the first half of this year, are you sure of that?
Jonathan Lim
Yeah we are still targeting a Q2 rollout of the data from the Phase I/IIa trial.
Eun Yang - Jefferies & Company
And just another question on products sales this year, I mean this quarter it was came around 98,000. I was just wondering that weakness was both HYLENEX weakness or from Cumulase or you can give a breakdown of where are the sales came from the two products?
- To read the full transcript on Seeking Alpha, click here »
